Pfizer racks up an FDA approval for eczema blockbuster hopeful crisaborole
Pfizer will now get a chance to see if the eczema drug crisaborole is really worth up to or beyond $2 billion in annual sales.
The FDA has approved the non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, which Pfizer snapped up last May when it acquired Anacor Pharmaceuticals for $5.2 billion. The drug will be sold as Eucrisa.
The drug came through back in mid-2015 in a pair of studies which enrolled more than 1,500 patients, beating out a placebo and posting an acceptable safety profile.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
